{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Dai Z"],"funding":["Shanghai Municipal Science and Technology Major Project","Clinical Research Plan of Shanghai Hospital Development Center","National Natural Science Foundation of China","Clinical and Scientific Innovation Project of Shanghai Hospital Development Center","National Key Research and Development Program of China","Xuhui District Artificial Intelligence Medical Hospital Cooperation Project","the Scientific Innovation Project of Shanghai Education Committee"],"pagination":["61"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10908625"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["73(4)"],"pubmed_abstract":["<h4>Background</h4>Recent progressions in CAR-T cell therapy against pancreatic ductal adenocarcinoma (PDAC) remain disappointing, which are partially attributed to the immunosuppressive microenvironment including macrophage-mediated T cell repletion.<h4>Methods</h4>We first characterized the expression patterns of macrophage-relevant chemokines and identified CXCR2 as the key factor regulating T cell trafficking and tumor-specific accumulation in PDAC microenvironment. After that, we synthesized and introduced a CXCR2 expression cascade into Claudin18.2 CAR-T cells and compared the behaviors of CAR-T cells in vitro and in vivo. The therapeutic potential of CXCR2 CAR-T was evaluated in two different allogeneic models: subcutaneous allografts and metastatic PDAC models.<h4>Results</h4>The r"],"journal":["Cancer immunology, immunotherapy : CII"],"pubmed_title":["Ectopic CXCR2 expression cells improve the anti-tumor efficiency of CAR-T cells and remodel the immune microenvironment of pancreatic ductal adenocarcinoma."],"pmcid":["PMC10908625"],"funding_grant_id":["21JC1401500","82072693, 81902417, 82172884, U21A20374","SHDC2020CR1006A","SHDC12018109","2020YFA0803202","2019-01-07-00-07-E00057","2021-011"],"pubmed_authors":["Zou X","Wang R","Tasiheng Y","Ma M","Lin X","Chen Y","Wang X","Liu C","Yan Y","Dai Z","Cheng H","Yu X"],"additional_accession":[]},"is_claimable":false,"name":"Ectopic CXCR2 expression cells improve the anti-tumor efficiency of CAR-T cells and remodel the immune microenvironment of pancreatic ductal adenocarcinoma.","description":"<h4>Background</h4>Recent progressions in CAR-T cell therapy against pancreatic ductal adenocarcinoma (PDAC) remain disappointing, which are partially attributed to the immunosuppressive microenvironment including macrophage-mediated T cell repletion.<h4>Methods</h4>We first characterized the expression patterns of macrophage-relevant chemokines and identified CXCR2 as the key factor regulating T cell trafficking and tumor-specific accumulation in PDAC microenvironment. After that, we synthesized and introduced a CXCR2 expression cascade into Claudin18.2 CAR-T cells and compared the behaviors of CAR-T cells in vitro and in vivo. The therapeutic potential of CXCR2 CAR-T was evaluated in two different allogeneic models: subcutaneous allografts and metastatic PDAC models.<h4>Results</h4>The r","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2025-04-22T15:28:04.574Z","creation":"2025-04-06T01:24:54.739Z"},"accession":"S-EPMC10908625","cross_references":{"pubmed":["38430267"],"doi":["10.1007/s00262-024-03648-y"]}}